TB-HIV Factsheet 2018. Data Hub. (2018)
 |
Concerted and integrated efforts are needed to prevent and address both TB and TB-HIV burden in the region. 2 out of 3 TB infections globally are in Asia and the Pacific and 60% of MDR-TB burden is in this region. Globally, Asia and the Pacific is the home for 13% of PLHIV but 20% of TB-HIV co-infections are in this region. Systematic collaboration between TB-HIV programmes will save lives and improve the quality of life of people living with and affected by HIV and TB.
|
Compendium of WHO Guidelines and Associated Standards: Ensuring Optimum Delivery of the Cascade of Care for Patients with Tuberculosis, Second Edition. WHO. (2018)
 |
The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or symptoms of TB in seeking diagnosis, treatment and care; and includes key algorithms and cross-cutting elements that are essential to a patient-centered approach in the cascade of TB care.
|
Bending the Curve - Keeping our Promise of Ending TB in the South-East Asia Region on Time. WHO, Regional Office for South-East Asia. (2018)
 |
The WHO South-East Asia (SEA) Region has some of the highest TB-burden countries, and nearly half of all TB cases in the world are to be found in people from this Region. The Region has nearly half the global burden in terms of new cases (incidence), and close to 40% of the burden in terms of deaths due to TB. And this while only 26% of the global population lives in the Region.
Keywords: TB, drug-resistant, treatment, funding
|
Global Tuberculosis Report 2018. WHO. (2018)
 |
WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO’s Member States and broader development goals set by the United Nations.
Keywords: TB, prevention, diagnosis, treatment, drug-resistant
Download
|
Tuberculosis and HIV. UNAIDS. (2018)
 |
HIV-associated TB presents a risk to achieving the Sustainable Development Goals. Effective, sustained action is required to meet the needs of the most vulnerable populations.
Keywords: TB, PLHIV, treatment, diagnostic, deaths
|
Roadmap towards Ending TB in Children and Adolescents. WHO. (2018)
 |
The 2018 United Nations General Assembly High-Level Meeting (HLM) on Tuberculosis and the current revision of the Roadmap for childhood tuberculosis together present an important moment to consolidate and advance advocacy, commitment, resource mobilization and joint efforts by all stakeholders to provide health care and address the burden of TB among children
Keywords: TB, HIV, multidrug-resistant, treatment, advocacy
|
Multi-Country Western Pacific Integrated HIV/TB Programme Results Report 2015-2017. UNDP Pacific Office in Fiji. (2018)
 |
This document captures the achievements from 2015-2017 of the Multi-Country Western Pacific Integrated HIV/TB Programme. The programme improved the coverage and quality of HIV/TB prevention, treatment and care in 11 countries: Cook Islands, Federated States of Micronesia, Kiribati, Marshall Islands, Nauru, Niue, Palau, Samoa, Tonga, Tuvalu and Vanuatu.
|
Handbook for the Use of Digital Technologies to Support Tuberculosis Medication Adherence. WHO. (2018)
 |
TB patients and health-care providers are surrounded by information and communication technologies. They will be using these tools increasingly to obtain better care. However, in doing so they are often faced with basic questions, such as: Which application is best suited to my circumstances? What is the evidence for effectiveness? How do I implement it? Who will pay?
This handbook aims to address some of these questions. It focuses specifically on three technologies that are being widely used to help TB patients complete their treatment over the many months that their regimens last.
|
Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis. WHO. (2017)
 |
The report – “Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis” – shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance. Most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions. The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as posing the greatest threat to health, including drug-resistant tuberculosis which kills around 250 000 people each year. In addition to multidrug-resistant tuberculosis, WHO has identified 12 classes of priority pathogens – some of them causing common infections such as pneumonia or urinary tract infections – that are increasingly resistant to existing antibiotics and urgently in need of new treatments.
|
Bending the Curve - Ending TB: Annual Report 2017. WHO, Regional Office for South-East Asia. (2017)
 |
This is the second SEAR TB Report as we take first steps into the post 2015 era of the SDGs. In 2015, there was an estimated 4.74 million incidence of TB in the SEA Region, including HIV+TB co-infection. The total number of new cases notified to National TB programmes in the Region were around 2.65 million in appear staggering despite a reasonably good performance. Three countries that are poised well to eliminating TB by 2030 are Maldives, Bhutan and Sri Lanka. Nepal too is doing well despite the twin challenges of its mountainous terrain and coping with a major natural disaster. Timor-Leste, though small in terms of absolute TB numbers, faces a major challenge in bringing down its incidence rate.
|
Pages
